

A Palladium-Catalyzed Three-Component Reaction for the Preparation of Quinazolin-4(3H)-imines

Guanyinsheng Qiu,[†] Gang Liu,^{†,§} Shouzhi Pu,^{*,§} and Jie Wu^{*,†,‡}

[†] *Department of Chemistry, Fudan University, 220 Handan Road, Shanghai 200433, China*

[§] *Jiangxi Key Laboratory of Organic Chemistry, Jiangxi Science & Technology Normal University,
Nanchang 330013, China* [‡] *State Key Laboratory of Organometallic Chemistry, Shanghai
Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China*

jie_wu@fudan.edu.cn; pushouzhi@yahoo.com.cn



Supporting Information

1. General experimental methods (S2).
2. General experimental procedure and characterization data (S2-S10).
3. ¹H and ¹³C NMR spectra of compounds **1** and **4** (S11-S54).

General experimental methods:


Unless otherwise stated, all commercial reagents were used as received. All solvents were dried and distilled according to standard procedures. Flash column chromatography was performed using silica gel (60-Å pore size, 32–63µm, standard grade). Analytical thin-layer chromatography was performed using glass plates pre-coated with 0.25 mm 230–400 mesh silica gel impregnated with a fluorescent indicator (254 nm). Thin layer chromatography plates were visualized by exposure to ultraviolet light. Organic solutions were concentrated on rotary evaporators at ~20 Torr at 25–35°C. Nuclear magnetic resonance (NMR) spectra are recorded in parts per million from internal tetramethylsilane on the δ scale. ^1H and ^{13}C NMR spectra were recorded in CDCl_3 on a Bruker DRX-400 spectrometer operating at 400 MHz and 100 MHz, respectively. All chemical shift values are quoted in ppm and coupling constants quoted in Hz. High resolution mass spectrometry (HRMS) spectra were obtained on a micrOTOF II Instrument.

The carbodiimides **1** were synthesized according to literature method (F. Zeng and H. Alper, *Org. Lett.* 2010, **12**, 1188.)




2-Bromo-N-((phenylimino)methylene)aniline **1a** (X. Lv and W. Bao, *J. Org. Chem.* 2009, **74**, 5618.)

^1H NMR (400 MHz, CDCl_3) δ 6.85 (t, $J = 7.2$ Hz, 1H), 7.16–7.22 (m, 4H), 7.27–7.34 (m, 3H), 7.79 (d, $J = 7.6$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 93.6, 124.5, 124.7, 125.7, 126.7, 129.2, 129.4, 132.6, 137.6, 139.5, 140.9. LC-MS (ESI): 273 ($\text{M}^+ + \text{H}$).




2-Bromo-N-((butylimino)methylene)aniline **1b**

^1H NMR (400 MHz, CDCl_3) δ 0.93 (t, $J = 7.2$ Hz, 3H), 1.42-1.44 (m, 2H), 1.64-1.67 (m, 2H), 3.44 (t, $J = 6.4$ Hz, 2H), 6.76-6.79 (m, 1H), 7.15 (d, $J = 7.6$ Hz, 1H), 7.23-7.27 (m, 1H), 7.75 (d, $J = 8.0$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.5, 19.8, 33.0, 46.2, 93.1, 123.5, 125.6, 129.0, 138.0, 139.2, 142.9. LC-MS (ESI): 253 ($\text{M}^+ + \text{H}$); HRMS Calcd for $\text{C}_{11}\text{H}_{14}\text{BrN}_2$ (ESI, $\text{M}^+ + \text{H}$): 253.0340; Found: 253.0346.



2-Bromo-4-fluoro-N-((phenylimino)methylene)aniline **1c**


^1H NMR (400 MHz, CDCl_3) δ 6.96-7.00 (m, 1H), 7.16-7.22 (m, 4H), 7.30-7.34 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 115.4 (d, $J = 14$ Hz), 120.2 (d, $J = 25$ Hz), 124.1, 124.4, 125.6, 125.7, 126.2, 129.5, 137.6, 138.3, 159.8 (d, $J = 259$ Hz). LC-MS (ESI): 291 ($\text{M}^+ + \text{H}$); HRMS Calcd for $\text{C}_{13}\text{H}_9\text{BrFN}_2$ (ESI, $\text{M}^+ + \text{H}$): 290.9933; Found: 290.9947.



2-Bromo-4-methyl-N-((phenylimino)methylene)aniline **1d** (X. Lv and W. Bao, *J. Org. Chem.* 2009, **74**, 5618.)


^1H NMR (400 MHz, CDCl_3) δ 2.28 (s, 3H), 7.10-7.13 (m, 2H), 7.15 (m, 3H), 7.30-7.34 (m, 2H), 7.63 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 20.4, 93.4, 124.3, 124.4, 125.6, 129.4, 130.0, 136.9, 137.9, 139.7. LC-MS (ESI): 287 ($\text{M}^+ + \text{H}$).

General Procedure for the Palladium-Catalyzed Three-Component Reaction of Carbodiimide 1, Isocyanide 2, and Nucleophile 3




$\text{Pd}(\text{OAc})_2$ (10 mol %), PCy_3 (20 mol %), and Cs_2CO_3 (2 equiv) were added into a solution of carbodiimide **1** (0.2 mmol) in dry toluene (3.0 mL). Subsequently nucleophile **2** (3 equiv) and isocyanide **3** (1.5 equiv) were added. The mixture was

stirred at reflux under N₂. After completion of the reaction as indicated by TLC, the solvent was evaporated and the residue was purified on silica gel to provide the desired product **4**.




N-(3-Phenyl-2-(pyrrolidin-1-yl)quinazolin-4(3*H*)-ylidene)butan-1-amine **4a**

¹H NMR (400 MHz, CDCl₃) δ 0.89 (t, *J* = 7.2 Hz, 3H), 1.35-1.42 (m, 2H), 1.57-1.75 (m, 6H), 3.04-3.15 (m, 3H), 3.48-3.74 (m, 3H), 6.97 (t, *J* = 6.8 Hz, 7.2 Hz, 1H), 7.23-7.45 (m, 7H), 7.70 (d, *J* = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 13.9, 20.4, 25.4, 35.0, 49.1, 50.7, 118.1, 120.4, 123.4, 124.6, 126.3, 127.6, 127.9, 129.5, 131.2, 141.6, 148.8, 154.4; LC-MS (ESI): 347 (M⁺+H); HRMS Calcd for C₂₂H₂₇N₄ (ESI, M⁺+H): 347.2236; Found: 347.2236.



N-(3-Phenyl-2-(pyrrolidin-1-yl)quinazolin-4(3*H*)-ylidene)pentan-1-amine **4b**


¹H NMR (400 MHz, CDCl₃) δ 0.0725 (m, 3H), 0.78-0.87 (m, 3H), 1.59-1.67 (m, 4H), 1.84-1.97 (m, 1H), 2.99-3.23 (m, 4H), 3.54-3.71 (m, 4H), 6.97 (t, *J* = 6.8 Hz, 7.2 Hz, 1H), 7.18-7.45 (m, 7H), 7.70 (d, *J* = 8.0 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 1.11, 14.3, 22.6, 25.4, 32.6, 49.3, 51.1, 118.3, 120.5, 123.6, 124.7, 126.5, 127.8, 128.0, 129.7, 131.4, 141.7, 148.9, 153.4; LC-MS (ESI): 361 (M⁺+H); HRMS Calcd for C₂₃H₂₉N₄ (ESI, M⁺+H): 361.2392; Found: 361.2392.



2-Methyl-*N*-(3-phenyl-2-(pyrrolidin-1-yl)quinazolin-4(3*H*)-ylidene)propan-2-amine


4c

^1H NMR (400 MHz, CDCl_3) δ 1.41 (s, 9H), 1.79-1.85 (m, 4H), 3.30-3.38 (m, 4H), 6.92 (t, $J = 7.2$ Hz, 7.6 Hz, 1H), 7.05-7.28 (m, 7H), 7.61 (d, $J = 8.0$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 25.4, 31.4, 48.4, 55.4, 121.0, 122.7, 123.2, 123.6, 124.2, 127.4, 128.6, 130.8, 141.9, 145.6, 148.1, 153.6; LC-MS (ESI): 347 ($\text{M}^+ + \text{H}$); HRMS Calcd for $\text{C}_{22}\text{H}_{27}\text{N}_4$ (ESI, $\text{M}^+ + \text{H}$): 347.2236; Found: 347.2240.




N-(3-Phenyl-2-(piperidin-1-yl)quinazolin-4(3*H*)-ylidene)butan-1-amine **4d**

^1H NMR (400 MHz, CDCl_3) δ 0.90 (t, $J = 7.2$ Hz, 3H), 1.10-1.21 (m, 3H), 1.35-1.40 (m, 3H), 1.57-1.62 (m, 4H), 3.09-3.19 (m, 3H), 3.34-3.38 (m, 1H), 3.38-3.48 (m, 1H), 3.69-3.72 (m, 1H), 7.04-7.11 (m, 2H), 7.30-7.37 (m, 4H), 7.46-7.48 (m, 2H), 7.69 (d, $J = 8.0$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.4, 21.0, 24.5, 25.4, 31.0, 48.1, 55.5, 122.1, 122.5, 123.6, 123.9, 126.5, 128.5, 130.6, 142.5, 145.5, 146.6, 155.4; LC-MS (ESI): 361 ($\text{M}^+ + \text{H}$); HRMS Calcd for $\text{C}_{23}\text{H}_{29}\text{N}_4$ (ESI, $\text{M}^+ + \text{H}$): 361.2392; Found: 361.2388.




2-Methyl-*N*-(3-phenyl-2-(piperidin-1-yl)quinazolin-4(3*H*)-ylidene)propan-2-amine **4e**

^1H NMR (400 MHz, CDCl_3) δ 1.36 (s, 9H), 1.42-1.58 (m, 6H), 3.45-3.50 (m, 4H), 6.97-7.29 (m, 8H), 7.66 (d, $J = 7.2$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 24.6, 25.4, 31.0, 48.1, 55.5, 122.1, 122.5, 123.7, 123.9, 126.7, 128.5, 130.6, 142.7, 145.2, 146.9, 155.5; LC-MS (ESI): 361 ($\text{M}^+ + \text{H}$); HRMS Calcd for $\text{C}_{23}\text{H}_{29}\text{N}_4$ (ESI, $\text{M}^+ + \text{H}$): 361.2392; Found: 361.2392.




2-Methyl-*N*-(2-morpholino-3-phenylquinazolin-4(3*H*)-ylidene)propan-2-amine **4f**

^1H NMR (400 MHz, CDCl_3) δ 1.35 (s, 9H), 3.44-3.46 (m, 4H), 3.56-3.57 (m, 4H), 7.04 (t, J = 7.6 Hz, 1H), 7.11 (t, J = 7.2 Hz, 1H), 7.19-7.34 (m, 6H), 7.68 (d, J = 8.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 31.0, 47.8, 55.1, 66.4, 122.4, 123.3, 124.1, 124.4, 124.9, 127.3, 128.4, 130.8, 142.3, 144.8, 146.8, 155.3; LC-MS (ESI): 363 ($\text{M}^+\text{+H}$); HRMS Calcd for $\text{C}_{22}\text{H}_{27}\text{N}_4\text{O}$ (ESI, $\text{M}^+\text{+H}$): 363.2185; Found: 363.2182.



N-(2-(Azepan-1-yl)-3-phenylquinazolin-4(3*H*)-ylidene)-2-methylpropan-2-amine **4g**


^1H NMR (400 MHz, CDCl_3) δ 1.42 (s, 9H), 1.55-1.59 (m, 4H), 1.60-1.71 (m, 4H), 3.59-3.70 (m, 4H), 6.91 (t, J = 7.2 Hz, 7.6 Hz, 1H), 6.97 (t, J = 6.8 Hz, 7.2 Hz, 1H), 7.05-7.09 (m, 3H), 7.18-7.24 (m, 3H), 7.59 (d, J = 7.6 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 27.6, 28.3, 31.1, 48.7, 56.1, 119.8, 121.5, 123.0, 123.3, 124.4, 126.6, 128.7, 130.6, 142.3, 145.6, 147.4, 155.0; LC-MS (ESI): 375 ($\text{M}^+\text{+H}$); HRMS Calcd for $\text{C}_{24}\text{H}_{31}\text{N}_4$ (ESI, $\text{M}^+\text{+H}$): 375.2549; Found: 375.2556.



4-(*tert*-Butylimino)-*N,N*-diisopropyl-3-phenyl-3,4-dihydroquinazolin-2-amine **4h**


^1H NMR (400 MHz, CDCl_3) δ 1.27 (d, J = 6.8 Hz, 12 H), 1.42 (s, 9H), 3.87-3.91 (m, 2H), 6.90 (t, J = 7.2 Hz, 1H), 6.97 (t, J = 4.0 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H), 7.19-7.20 (m, 4H), 7.23-7.30 (m, 1H), 7.53 (d, J = 8.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 21.2, 31.1, 48.3, 55.6, 121.7, 123.6, 123.9, 124.0, 126.8, 128.4, 130.3, 142.9,

146.1, 147.7, 153.5; LC-MS (ESI): 377 ($M^+ + H$); HRMS Calcd for $C_{24}H_{33}N_4$ (ESI, $M^+ + H$): 377.2705; Found: 377.2699.



N-(2-(Indolin-1-yl)-3-phenylquinazolin-4(3*H*)-ylidene)-2-methylpropan-2-amine **4i**


1H NMR (400 MHz, $CDCl_3$) δ 1.42 (s, 9H), 2.94 (t, J = 8.4 Hz, 2H), 3.60 (t, J = 8.0 Hz, 8.4 Hz, 2H), 6.86 (t, J = 7.2, 7.6 Hz, 1H), 7.07-7.24 (m, 6H), 7.37-7.42 (m, 4H), 7.69 (d, J = 7.6 Hz, 1H), 7.76 (d, J = 8.4 Hz, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 28.7, 31.1, 50.7, 54.7, 115.4, 121.5, 122.0, 122.2, 124.5, 124.6, 125.6, 125.7, 127.0, 127.9, 128.2, 130.8, 131.3, 141.3, 144.5, 147.4, 151.2; LC-MS (ESI): 395 ($M^+ + H$); HRMS Calcd for $C_{26}H_{27}N_4$ (ESI, $M^+ + H$): 395.2236; Found: 395.2224.



Methyl


1-(4-(*tert*-butylimino)-3-phenyl-3,4-dihydroquinazolin-2-yl)pyrrolidine-2-carboxylate **4j**

1H NMR (400 MHz, $CDCl_3$) δ 1.38 (s, 9H), 1.72-2.19 (m, 4H), 2.79-2.81 (m, 1H), 3.10-3.20 (m, 1H), 3.76 (s, 3H), 4.66 (t, J = 6.4 Hz, 7.2 Hz, 1H), 6.93 (t, J = 7.2, 7.6 Hz, 1H), 7.12 (t, J = 8.4 Hz, 1H), 7.25-7.31 (m, 3H), 7.46-7.52 (m, 3H), 7.59 (d, J = 8.0 Hz, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 25.2, 29.4, 31.1, 49.0, 51.9, 54.5, 61.0, 120.7, 122.4, 124.0, 125.2, 126.4, 128.0, 128.1, 141.4, 148.2, 152.6, 174.1; LC-MS (ESI): 405 ($M^+ + H$); HRMS Calcd for $C_{24}H_{29}N_4O_2$ (ESI, $M^+ + H$): 405.2291; Found: 405.2297.




4-(*tert*-Butylimino)-3-phenyl-*N*-(*p*-tolyl)-3,4-dihydroquinazolin-2-amine **4l**

^1H NMR (400 MHz, CDCl_3) δ 1.23 (s, 9H), 2.26 (s, 3H), 7.03-7.85 (m, 13H); ^{13}C NMR (100 MHz, CDCl_3) δ 22.6, 29.6, 31.4, 111.6, 119.3, 120.6, 122.3, 123.0, 125.3, 126.6, 128.6, 129.1, 129.5, 129.7, 130.3, 131.3, 133.0, 141.4, 148.4; LC-MS (ESI): 383 ($\text{M}^+\text{+H}$); HRMS Calcd for $\text{C}_{25}\text{H}_{27}\text{N}_4$ (ESI, $\text{M}^+\text{+H}$): 383.2236; Found: 383.2242.



N-(3-Butyl-2-(pyrrolidin-1-yl)quinazolin-4(3*H*)-ylidene)-2-methylpropan-2-amine **4m**


^1H NMR (400 MHz, CDCl_3) δ 0.75 (t, $J = 7.2$ Hz, 7.6 Hz, 3H), 1.04-1.09 (m, 2H), 1.33-1.35 (m, 2H), 1.46 (s, 9H), 1.87 (m, 4H), 3.50-3.58 (m, 6H), 6.98 (t, $J = 7.2$ Hz, 1H), 7.14 (d, $J = 8.0$ Hz, 1H), 7.26-7.31 (m, 1H), 7.85 (d, $J = 7.6$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.6, 19.8, 25.5, 29.7, 30.2, 30.8, 48.4, 54.4, 122.0, 123.5, 125.3, 130.3, 139.5, 145.3, 146.6, 155.5; LC-MS (ESI): 327 ($\text{M}^+\text{+H}$); HRMS Calcd for $\text{C}_{20}\text{H}_{31}\text{N}_4$ (ESI, $\text{M}^+\text{+H}$): 327.2549; Found: 327.2549.



N-(2-(Azepan-1-yl)-3-butylquinazolin-4(3*H*)-ylidene)-2-methylpropan-2-amine **4n**


^1H NMR (400 MHz, CDCl_3) δ 0.74 (t, $J = 6.8$ Hz, 7.2 Hz, 3H), 1.04-1.09 (m, 2H), 1.18-1.34 (m, 4H), 1.41 (s, 9H), 1.44-1.90 (m, 6H), 3.49-3.53 (m, 6H), 6.98 (t, $J = 7.2$ Hz, 8.0 Hz, 1H), 7.12 (d, $J = 7.6$ Hz, 1H), 7.25-7.30 (m, 1H), 7.83 (d, $J = 7.6$ Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 13.5, 19.8, 27.4, 27.7, 28.7, 30.1, 30.7, 49.7, 54.5, 122.2, 123.7, 125.2, 130.3, 145.6, 146.6, 157.5; LC-MS (ESI): 355 ($\text{M}^+\text{+H}$); HRMS

Calcd for $C_{22}H_{35}N_4$ (ESI, $M^+ + H$): 355.2862; Found: 355.2857.




N-(6-Fluoro-3-phenyl-2-(pyrrolidin-1-yl)quinazolin-4(3*H*)-ylidene)-2-methylpropan-2-amine **4o**

1H NMR (400 MHz, $CDCl_3$) δ 1.41 (s, 9H), 1.86-1.88 (m, 4H), 3.43-3.44 (m, 4H), 6.96-7.11 (m, 5H), 7.24 (t, $J = 6.4$ Hz, 7.2 Hz, 2H), 7.31-7.34 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 25.2, 31.1, 48.1, 55.7, 112.9 (d, $^2J_{CF} = 23$ Hz), 117.8 (d, $^2J_{CF} = 23$ Hz), 121.6, 123.9, 124.5, 124.6, 128.7, 141.6, 143.7, 144.4, 153.1, 157.8 (d, $^1J_{CF} = 284$ Hz); LC-MS (ESI): 365 ($M^+ + H$); HRMS Calcd for $C_{22}H_{26}FN_4$ (ESI, $M^+ + H$): 365.2142; Found: 365.2144.



N-(2-(Azepan-1-yl)-6-fluoro-3-phenylquinazolin-4(3*H*)-ylidene)-2-methylpropan-2-amine **4p**


1H NMR (400 MHz, $CDCl_3$) δ 1.42 (s, 9H), 1.52-1.58 (m, 4H), 1.59-1.74 (m, 5H), 3.63-3.65 (m, 3H), 6.92-6.99 (m, 5H), 7.19-7.24 (m, 2H), 7.30-7.32 (m, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 27.6, 28.4, 31.0, 48.6, 55.6, 112.4 (d, $^2J_{CF} = 24$ Hz), 117.6 (d, $^2J_{CF} = 23$ Hz), 119.0, 123.0, 124.4, 128.9, 142.1, 143.2, 144.5, 154.5, 158.2 (d, $^1J_{CF} = 284$ Hz); LC-MS (ESI): 393 ($M^+ + H$); HRMS Calcd for $C_{24}H_{30}FN_4$ (ESI, $M^+ + H$): 393.2455; Found: 393.2447.



2-Methyl-*N*-(6-methyl-3-phenyl-2-(pyrrolidin-1-yl)quinazolin-4(3*H*)-ylidene)propan-


2-amine **4q**

^1H NMR (400 MHz, CDCl_3) δ 1.42 (s, 9H), 1.85-1.88 (m, 4H), 2.28 (s, 3H), 3.43-3.46 (m, 4H), 7.00-7.12 (m, 5H), 7.20-7.25 (m, 2H), 7.41 (s, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 20.9, 25.3, 31.2, 48.0, 55.6, 121.6, 123.2, 123.6, 127.0, 128.9, 130.7, 131.7, 141.9, 145.2, 145.8, 153.1; LC-MS (ESI): 361 ($\text{M}^+\text{+H}$); HRMS Calcd for $\text{C}_{23}\text{H}_{29}\text{N}_4$ (ESI, $\text{M}^+\text{+H}$): 361.2392; Found: 361.2376.



N-(2-(Benzyloxy)-3-phenylquinazolin-4(3*H*)-ylidene)-2-methylpropan-2-amine **4r**

^1H NMR (400 MHz, CDCl_3) δ 1.18 (s, 9H), 5.37 (s, 2H), 7.11-7.16 (m, 4H), 7.22-7.28 (m, 3H), 7.26-7.30 (m, 2H), 7.34-7.36 (m, 3H), 7.41-7.45 (m, 1H), 7.94 (d, J = 8.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 31.1, 53.3, 68.4, 120.4, 122.3, 125.3, 126.8, 126.9, 127.5, 127.9, 128.2, 129.0, 129.6, 131.3, 136.5, 139.8, 142.9, 146.8, 154.0; LC-MS (ESI): 384 ($\text{M}^+\text{+H}$); HRMS Calcd for $\text{C}_{25}\text{H}_{26}\text{N}_3\text{O}$ (ESI, $\text{M}^+\text{+H}$): 384.2076; Found: 384.2083.



N-(2-(4-(*tert*-Butyl)phenoxy)-3-phenylquinazolin-4(3*H*)-ylidene)-2-methylpropan-2-amine **4s**

^1H NMR (400 MHz, CDCl_3) δ 1.22 (s, 9H), 1.29 (s, 9H), 7.01 (d, J = 8.4 Hz, 2H), 7.07-7.15 (m, 2H), 7.24-7.39 (m, 8H), 7.94 (d, J = 8.0 Hz, 1H); ^{13}C NMR (100 MHz, CDCl_3) δ 31.0, 31.4, 34.4, 53.3, 120.5, 120.7, 122.7, 125.8, 126.0, 126.9, 128.3, 129.0, 129.4, 131.2, 139.8, 142.9, 146.6, 147.7, 150.0, 154.1; LC-MS (ESI): 426 ($\text{M}^+\text{+H}$); HRMS Calcd for $\text{C}_{28}\text{H}_{32}\text{N}_3\text{O}$ (ESI, $\text{M}^+\text{+H}$): 426.2545; Found: 426.2551.

